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Global Inequalities in Access
to Cardiovascular Health Care
Our Greatest Challenge
Rohina Joshi, MBBS, MPH, PHD,* Stephen Jan, MEC, PHD,* Yangfeng Wu, MD, PHD,†
Stephen MacMahon, DSC, PHD, FACC, FAHA, FCSANZ*
Sydney, Australia; and Peking, China
Cardiovascular disease (CVD) was the leading cause of death globally in 2005, responsible for 17.5 million
deaths, more than 80% of which occurred in low- and middle-income countries (LMIC). In these regions, CVD
occurs at a much younger age than in high-income countries, thereby contributing disproportionately to lost po-
tential years of healthy life as well as lost economic productivity. Many effective interventions for CVD prevention
and management are now affordable for all but the very poorest countries, but large treatment gaps still exist
because of poor prescribing practices, limited availability of medicines, and lack of appropriately skilled health
care providers. Despite the increasing awareness of the growing epidemic of CVD in LMIC, this public health pri-
ority has received little attention from those who determine the international health agenda. Although the bur-
den of CVD is already enormous in developing countries, there exists a window of opportunity to prevent the epi-
demic reaching its full potential magnitude. This requires the rapid deployment of strategies already proven to
be effective in high-income countries. Such strategies need to be tailored for LMIC for them to be affordable,
effective, and accessible to disadvantaged groups and the burgeoning middle classes. Ideally, the control of CVD
in these countries would involve a dual approach in which evidence-based clinical strategies for CVD prevention
and treatment are complemented by evidence-based population level strategies. We propose that upgrading
primary health care services is a central requirement for the control of the CVD epidemics facing the developing
world. (J Am Coll Cardiol 2008;52:1817–25) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.049o
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blthough it is now well recognized that cardiovascular
isease (CVD) is a major and growing health problem for
ow- and middle-income countries (LMIC), it is less well
ecognized that it is also a major cause of the widening
nequity in the health status of the rich and poor. No longer
an CVD be considered a problem of affluence (1). In most
igh-income countries, rates of CVD reached a peak in the
iddle of the 20th century, and have declined progressively
ver since, because of a combination of successful
opulation-wide preventive strategies, effective primary and
econdary preventive health care, and improved treatment
or acute cardiovascular events. However, although cardio-
ascular mortality has decreased by around three-quarters
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rlando, Florida.C
Manuscript received May 16, 2008; revised manuscript received July 31, 2008,
ccepted August 5, 2008.ver the past 3 decades in countries such as Australia,
anada, the United Kingdom, and the U.S., rates in many
MIC have increased over the same period (2,3). At the
eginning of the 21st century, this epidemic is gaining pace
nd is already the leading cause of death in many LMIC.
lthough safe and effective preventive treatments are available
t low cost, it is still the case that most individuals for whom
uch treatments are recommended do not receive any care (4).
ence, interventions that have been so successfully deployed in
igh-income settings to curb the growth of CVD are still
argely missing from the health care services of most LMIC.
The development and implementation of strategies to
revent and treat CVD in LMIC will require major efforts
o direct scarce resources to interventions that are cost
ffective, culturally appropriate, and sustainable. This has
mplications not only for resources currently directed toward
he health problems associated with poverty, but also for
esources currently directed toward high-technology proce-
ures such as percutaneous coronary interventions (5). In
his article we review the burden of CVD in LMIC,
escribe the escalating inequalities in access to primary
VD health care, and discuss practical solutions that could
e implemented to reduce such inequalities, using rural
hina as an example.
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Global Inequalities in Access to Cardiovascular Health Care December 2, 2008:1817–25The Problem
of CVD in LMIC
Disease burden. Worldwide in
2005, CVD was estimated to
have caused approximately 17.5
million deaths, of which more
than 80% occurred in LMIC (6).
By 2030, the number of cardio-
vascular deaths is projected to
increase to 23 million, with about
85% occurring in these countries
(Fig. 1) (7). This increase is of
roughly equal magnitude to the
rojected increase in deaths from human immunodeficiency
irus (HIV) infection over the same period. Already, CVD
s the leading cause of death in China (8) and India (9), the
orld’s 2 most populous countries. Even in countries such as
outh Africa, where deaths from HIV still dominate, the
ate of deaths from high blood pressure has increased by
5% in less than a decade (10). The CVD burden suffered
y many LMIC now exceeds that suffered by many high-
ncome countries. For example, in 2003, the disability-
djusted life years (DALYs) lost because of coronary heart
isease were 27 and 20 per 1,000 population in the Russian
ederation and India compared with 5 and 8 per 1,000 in
ustralia and the U.S., respectively (Table 1). Similarly,
ALYs lost because of stroke in China were 12 in 1,000
ompared with 4 in 1,000 in the United Kingdom (11).
Fueling the increasing mortality rates from CVD in
MIC are upward trends in the prevalence of risk factors
uch as obesity, high blood pressure, tobacco smoking, and
Figure 1 Global CVD Mortality
CVD  cardiovascular disease.
Abbreviations
and Acronyms
CVD  cardiovascular
disease
DALYS  disability-adjusted
life years
GDP  gross domestic
product
LMIC  low- and middle-
income countries
WHO  World Health
Organizationiiabetes. Although similar trends for some of these risk
actors, such as obesity, are present in high-income coun-
ries, the rate of increase in the prevalence of risk factors is
igher in developing countries (12). In China, for example,
besity has increased 4-fold in the last 2 decades (13).
onsequently, the average level of total cholesterol among
hinese men age 25 to 64 years has increased from 4.15
mol/l in 1984 to 5.25 mmol/l in 1999 (11). In India, the
revalence of diabetes is projected to increase from 32
illion in 2000 to 79 million in 2030 (14). By 2025, the
revalence of hypertension is expected to increase to 500
illion in India and China (15). Even in settings where risk
actor rates are already high, the trends are not encouraging;
or example, over the past decade the prevalence of smoking
mong adult men in Russia has increased from 57% to 62%
16), in contrast to Australia, where it decreased from 28%
o 25% (17). Furthermore, within these countries, individ-
als of lower socioeconomic status are often more vulnerable
o CVD as a consequence of greater exposure to risk factors
uch as smoking and reduced access to health care and
ealth education (3).
conomic burden. CVD has a huge economic impact on
ndividuals, households, and countries. The effects are
articularly marked in LMIC, where CVD more frequently
ffects those of working age, and for this reason contributes
isproportionately to lost potential years of healthy life. In
uch countries, approximately one-half of all cardiovascular
eaths occur before the age of 70 years, compared with just
ne-quarter in high-income countries (12). An example of
he stark difference between high- and lower-income re-
ions is provided by Tanzania, where stroke-related death
mong people age 15 to 59 years is 3 to 8 times higher than
hat in England and Wales (12). Similarly, in India, CVD
ortality in the working age population (30 to 59 years) is
wice that in the U.S. (18).
Recent estimates of foregone gross domestic product
GDP) associated with CVD and diabetes for 23 LMIC
ighlight how such illnesses can significantly impair eco-
omic growth (19). It was estimated that the aggregate loss
n GDP across these countries in 2006 as a consequence of
hese diseases was $6.8 billion, with China, India, and
ussia each incurring annual losses of over $1 billion.
urthermore, it is projected that if there is no change in
isease trends, the annual foregone GDP across these 23
ountries will increase to 150% of current levels by 2015,
esulting in a cumulative loss over this 10-year period of $84
illion. Hence, efforts to produce even modest reductions in
ge-specific disease rates could have very large economic
mpacts. For example, a 2% annual reduction in cardiovas-
ular death rates, as proposed by the World Health Orga-
ization (WHO) in 2005 (20), may avert the loss of $8.1
illion over a decade, including $1.36 billion in China,
1.64 billion in India, and $1.49 billion in Russia (Table 2).
However, such estimates of the costs of illness are
nreliable and often tend to underestimate macroeconomic
mpacts (21). For instance, coping strategies used by house-
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December 2, 2008:1817–25 Global Inequalities in Access to Cardiovascular Health Careolds in response to the treatment costs and loss of income
requently involve the use of savings and the removal of
hildren from schools (3), each of which have long-term
mplications in terms of investment and human capital
evelopment that are often not well taken into account.
uch issues might explain some of the wide differences in
vailable estimates.
reatment gaps. Secondary prevention has contributed sub-
tantially to the dramatic decline in CVD mortality rates in
DALYs Lost Because of Heart Disease and Strok
Table 1 DALYs Lost Because of Heart Disea
DALYs Lost per 1,000
Population Because
of Heart Disease
High-income countries
Australia 5
United Kingdom 7
U.S. 8
Low-income countries
China 4
India 20
Russian Federation 27
South Africa 9
Data from The Atlas of Heart Disease and Stroke (11).
DALYs  disability-adjusted life years.
ost of Cardiovascular Disease in Terms of Lost GDP in 23 Low- an
Table 2 Cost of Cardiovascular Disease in Terms of Lost GDP i
Baseline
Foregone GDP,*
U.S. $ Billions 2015 as
of 2006
2006 2015
China 1.01 1.84 1
India 1.35 1.96 1
Russia 1.49 1.64 1
Brazil 0.33 0.5 1
Indonesia 0.33 0.53 1
Mexico 0.48 0.89 1
Turkey 0.39 0.52 1
Pakistan 0.15 0.21 1
Thailand 0.12 0.18 1
Bangladesh 0.08 0.14 1
Ukraine 0.13 0.13 1
Egypt 0.11 0.14 1
Argentina 0.13 0.16 1
Burma 0.03 0.06 2
Iran 0.08 0.13 1
Poland 0.17 0.23 1
South Africa 0.16 0.21 1
Philippines 0.06 0.07 1
Colombia 0.07 0.1 1
Vietnam 0.02 0.03 2
Nigeria 0.12 0.12 1
Ethiopia 0.03 0.03 1
Democratic Republic of the Congo 0 0.03 1
Total 6.8 9.8ata from Table 2 of Abegunde et al. (19), with permission.
GDP  gross domestic product.igh-income countries such as the U.S. (22). Despite the
trength of scientific and economic evidence about the benefits
f aspirin, blood pressure-lowering drugs, and statins in sec-
ndary prevention, such treatments are underused in most
MIC (4). For example, a WHO study conducted in 10
eveloping countries indicated that fewer than one-fifth of all
atients with a previous history of CVD were on statins (4). In
recent study in rural Andhra Pradesh, India, CVD was found
o be the leading cause of death; however, fewer than one-sixth
d Stroke
LYs Lost per 1,000
opulation Because
of Stroke
Mortality Because of
Heart Disease and Stroke,
No. of Deaths (2002)
3 37,204
4 179,852
4 678,218
12 2,355,810
10 2,302,601
19 1,192,305
11 57,319
ddle-Income Countries
Low- and Middle-Income Countries
rio
Cumulative GDP Loss Averted if Global
Goal Were Achieved by 2015,
U.S. $ Billions (%)
rtion
ates
Cumulative GDP
Loss by 2015,
U.S. $ Billions
13.81 1.36 (9.83)
16.68 1.64 (9.83)
16.09 1.49 (9.26)
4.18 0.43 (10.23)
4.18 0.39 (9.33)
7.14 0.75 (10.58)
4.7 0.46 (9.72)
1.72 0.15 (8.62)
1.49 0.15 (10.20)
1.14 0.08 (7.14)
1.33 0.13 (9.43)
1.4 0.11 (8.89)
1.4 0.13 (9.09)
0.43 0.04 (9.09)
0.99 0.10 (10.53)
2.17 0.23 (10.53)
1.88 0.21 (11.43)
0.62 0.06 (9.09)
0.82 0.07 (8.33)
0.27 0.03 (12.50)
1.17 0.12 (10.00)
0.16 0.01 (7.50)
0.15 0.01 (7.90)
83.8 8.1 (9.5)e
se an
DA
Pd Mi
n 23
Scena
Propo
Estim
(%)
82
45
10
50
58
86
33
40
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Global Inequalities in Access to Cardiovascular Health Care December 2, 2008:1817–25f those with a previous cardiovascular event (mostly myocar-
ial infarction) were receiving antiplatelet therapy (23). In the
ame study, 50% of people with diabetes were aware of
heir condition, and of these, only two-thirds were
eceiving glucose-lowering therapy (24). Similar gaps
xist for the treatment of acute coronary syndrome. For
xample, in urban hospitals in China, management of
atients with acute coronary syndrome deviated signifi-
antly from current guidelines (25).
The reasons for these treatment gaps are complex. How-
ver, they are likely to include incomplete use of guidelines
y physicians and other health care workers, low treatment
dherence in part because of the cost of therapy, and the
tigma associated with taking medications over the long
erm in some settings. Studies examining the reasons for
oor implementation of guidelines suggest numerous barri-
rs at the patient, doctor, and health system level (26).
dditionally, some essential preventive medicines, such as
eneric diuretics, angiotensin-converting enzyme inhibitors,
nd statins, are not readily available through the public
ector in many developing countries (27). This could be
artially explained by budgetary constraints and out-of-
tock drugs attributable to poor estimates of use; however,
hese reasons need to be explored further (28). Although
uch drugs are more often available through the private
ector, their cost is generally several-fold higher, in part
ecause of the greater availability of drugs manufactured by
nternational pharmaceutical companies rather than drugs
anufactured by generic producers. In terms of the relative
ffordability of prevention treatments, there is enormous
Figure 2 Countries With a Critical Shortage of Health Care Pro
Based on data from Figure 2 of the report published in the World Health Report 20ariation worldwide. For example, a 1-month course of
ombination therapy for the secondary prevention of coro-
ary disease (generic aspirin, beta-blocker, angiotensin-
onverting enzyme inhibitor, and statin) varies in cost from
.5 days’ wages in Sri Lanka to 18 days’ wages in Malawi (28).
These treatment gaps can also be partially explained by the
imited availability of health care providers in most parts of the
eveloping world. For example, in Nigeria and India in 2006,
here were 3 and 6 physicians per 10,000 population, respec-
ively, whereas in the U.S. there were 26 per 10,000 population
29). This disparity reflects a broader imbalance in the avail-
bility of key health care providers (doctors, nurses, and
idwives) such that those countries with the lowest relative
eed have the highest numbers (Fig. 2). Within countries, the
istribution of health care workers also varies by locality: there
s typically a higher density of health workers in urban areas
ecause of better standards of living and higher salaries com-
ared with rural regions (29).
ack of investment. Despite increasing recognition of the
roblems arising from CVD in LMIC, few resources have
een directed toward the development of solutions. The lack of
nternational commitment is illustrated by the complete
bsence of CVD prevention and treatment in the Millen-
ium Development Goals (30). Similarly, chronic disease
ttracts only 5% of the entire WHO budget, and whereas
7.50 is spent per communicable disease death, only $0.50
s spent per death from chronic disease (31,32). Funding for
VD prevention and control also has been neglected by the
ajor health development funds, the World Bank, regional
evelopment banks, and bilateral aid programs. Another
s
9), with permission.vider
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December 2, 2008:1817–25 Global Inequalities in Access to Cardiovascular Health Carexample highlighting the low priority attached to the
roblem of CVD in LMIC is the exclusion by the Bill and
elinda Gates Foundation of CVD from their list of
riority diseases and conditions (33). Exacerbating this
ituation is the lack of capacity of governments within
MIC, such those in Africa and Southeast Asia, to redress
his imbalance. Despite accounting for more than one-third
f the world’s population, these governments have access to
nly 2% of the global health resources (34).
ddressing Inequalities
n Access to Cardiovascular Care
lthough the burden of CVD is already enormous in
MIC, there exists a window of opportunity for preventing
he epidemic from reaching its full potential magnitude
35). This requires the rapid deployment of strategies
lready proven to be effective in high-income countries.
uch strategies need to be tailored for LMIC for them to be
ffordable, effective, and accessible to disadvantaged groups
nd the burgeoning middle classes. Ideally, the control of
VD in LMIC would involve a dual approach in which
vidence-based clinical strategies for CVD prevention and
reatment are complemented by evidence-based population-
evel strategies. An example of a highly cost-effective
vidence-based population strategy that can reach a very
ide cross section of the population is legislation to control
he use of tobacco products through taxation and restric-
ions on advertising (36). There may be benefits of other
opulation strategies, such as legislation to control the salt
r fat content of processed foods or urban planning policies
o promote physical activity. However, the evidence base in
upport of these strategies is not as strong (37). Therefore,
eyond legislative change to reduce smoking, the most
mportant platform on which to base CVD prevention
fforts is clinical strategies to deliver proven and affordable
reventive strategies to those at high risk of fatal or
atastrophic events. We propose that upgrading primary
ealth care services is central to achieving this goal.
primary health care-based approach. As in high-
ncome countries, an effective and affordable primary health
are system is essential for the prevention and control of
VD. Wherever possible, the roles of primary health care
hould include, at a minimum: 1) targeted screening for the
dentification of individuals at very high risk of a fatal or
isabling cardiovascular event and the provision of cost-
ffective evidence-based preventive care; and 2) the identi-
cation of individuals with disabling symptomatic CVD,
nd either the provision of simple cost-effective treatments
or symptom control (e.g., nitrates for angina, loop diuretics
or symptoms of heart failure) or, where possible and
ppropriate, referral for specialist care.
Although the Declaration of Alma-Ata defines the concept
f primary health care and highlights the need for such care to
e universally accessible and affordable (38), few LMIC have
rimary health care systems that can reliably provide the aervices that are essential for the control of CVD (39). There
s clear evidence from systematic reviews that health systems
ith well-functioning primary care services are generally asso-
iated with better health outcomes, lower disparities in health,
nd lower costs of care (40). Among the reasons for this are
hat primary care can most effectively facilitate access to services
or deprived populations and is best able to deliver preventive
nterventions. Such preventive interventions together with the
arly treatment of overt illness can often substitute for more
xpensive and sometimes inappropriate specialist and hospital
reatment (40).
However, for this to be achieved on an appropriately broad
cale, major changes are required in the organization and
esource management of primary health care services. Histor-
cally, health systems in LMIC evolved to cater to infectious
iseases, injuries, and conditions associated with childbirth. In
any situations, this has led to primary health care typically
roviding episodic rather than continuing care, and to a failure
o develop reliable systems for maintaining medical records.
urthermore, in countries such as China, the lack of separation
etween prescriber and dispenser in primary health care set-
ings can lead to decisions about treatment being determined
y the price that can be charged rather than the cost-
ffectiveness (or even effectiveness) of the treatments available.
one of these factors is conducive to the delivery of reliable,
ost-effective primary cardiovascular health care.
ritical components. The key to achieving real reductions
n the CVD burden is through a well-functioning and
ccessible primary health care system that reliably delivers
ost-effective therapy to those most in need. The system
hould be geared toward using estimated absolute risk to
dentify individuals who would benefit most from medical
ntervention. The approach involves assessing risk on the
asis of multiple risk factors and CVD history, rather than
ocusing on elevations in single risk factors. Various risk
rediction tools, such as the Framingham risk prediction
ool, have been developed to calculate cardiovascular risk
nd tailor clinical management according to the level of risk.
ecause these tools have been developed in U.S. they are not
irectly applicable to all populations, particularly those in
hich the incidence of stroke is higher than that of coronary
eart disease; hence, they need to be recalibrated and
alidated using data from LMIC (41). The level of risk at
hich preventive treatments should be provided will differ
epending on disease burden and available resources. How-
ver, for all but the poorest nations, secondary prevention
ould be available to all individuals with a history of overt
VD. Table 3 sets out estimates of the cost effectiveness of
nterventions for CVD prevention in developing regions of
he world (42). Primary health care services should be
rganized such that core interventions can be delivered by
onphysician health care workers, ideally working under the
upervision of a physician, to enable the most efficient use of
carce resources including health care personnel (43). Im-
ortantly, this would reduce the costs and other barriers to
ccessing primary health care associated with traditional
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Global Inequalities in Access to Cardiovascular Health Care December 2, 2008:1817–25hysician-based models. Historically, the reduction in child-
ood diseases and the consequent gains in life expectancy in
MIC have been ascribed to strategies such as immunization
nd distribution of oral rehydration therapy that were per-
ormed by this type of primary health care worker.
A critical feature of any strategy for the prevention and
reatment of CVD is therefore to reorient primary care
ystems to more effectively deliver the care required for
hronic disease management. This requires several key
omponents, including appropriate screening tools and
reatment packages, improved health record systems, cost-
ffective drug distribution systems, systems to protect pa-
ients from prohibitive health care costs, and basic health
urveillance systems. The most appropriate screening tools
or use in resource-poor settings should involve simple
ethods focused on medical history and physical measure-
ents such as blood pressure and body mass, without
eliance on laboratory test results (44). Inexpensive urinary
ests for albuminuria and glycosuria may be cost-effective
dditions to a screening algorithm. Although laboratory
ests such as blood cholesterol and blood glucose may be
equired in some cases, the cost-effectiveness of these tests
eeds to be established for resource-poor settings. Treat-
ent regimens should be simple to administer and not
equire extensive titration. In this regard, the concept of a
VD “polypill” for disease prevention is attractive insofar as
he combination of aspirin, a statin, and 1 or more blood
ressure-lowering drugs at low dose should be well tolerated
nd should reduce CVD risk by at least one-half without any
eed for dose escalation (45). This combination can be man-
factured with generic components at very low cost and would
e suitable for a broad range of patients with a history of CVD
r at high risk of an initial cardiovascular event. Other
ost-effective strategies could include nicotine replacement
herapy for smoking cessation and low-dose, fixed-
ombination blood pressure-lowering therapy for those with
oderate to severe hypertension. The management of such
creening and intervention programs requires reliable medical
ecord systems, which often are missing from primary health
are services in resource-poor settings. Innovative approaches
Cost-Effectiveness of Combination Therapy ComN Treatment for CVD Preve tion in Developing
Table 3 Cost-Effectiveness of Combination TNo Treatment for CVD Prevention in
Secondary Prevention
East Asia and Pacific 336
East Europe and central Asia 362
Latin America and Caribbean 388
Middle East and northern Africa 341
South Asia 306
Sub-Saharan Africa 312
All values above are in U.S. $. Gross national income per head by region
national income per head. Drugs for secondary prevention: aspirin, angio
prevention: aspirin, angiotensin-converting enzyme inhibitor, calcium-chano the provision and maintenance of such systems are required. sndoubtedly, the ultimate solution will be the provision of
lectronic records developed specifically for use in these set-
ings. In addition to providing a system for maintaining
ecords, this approach also opens up the possibility of providing
lectronic decision support, including estimation of disease
isks and treatment recommendations based on guidelines (46).
The other critical components require higher-level policy
hange. Improvement of drug distribution systems is nec-
ssary in many countries because affordable generic products
re frequently unavailable through the public system and
naffordable through the private system (28). In some
ountries, the fees charged by multiple distribution net-
orks together with those charged by the dispenser can
ncrease the cost several-fold. In addition, there also are
roblems with drug quality, including counterfeit drug
roduction, in some countries. These issues can only be
esolved through legislative change and enforcement, al-
hough incentives to provide quality drug supplies through
fficient distribution systems also should be considered.
nnovative approaches to personal health care financing are
lso required, given that most health care expenditures are
ut of pocket in LMIC (47). Because it is unlikely that the
ublic health systems of most developing counties will pay
or primary CVD care in the foreseeable future, systems of
re-payment or community health insurance need to be
eveloped and deployed (48). However, it is critical that any
uch systems provide benefits for outpatient care and med-
cation, and not just hospitalization, which has been a focus
f community health insurance schemes in some regions.
Finally, better health information systems, such as mor-
ality surveillance systems, are required to inform health
olicies and set targets, as well as to monitor the effects of
ntervention programs (49). Countries with the highest
ortality levels, and arguably the greatest need for robust
ortality statistics, are the least likely to have civil registra-
ion systems with complete coverage of the population.
verall, only about one-third of the world’s deaths are
resently covered by civil registration systems (50). The
xtension of such systems to LMIC would greatly enhance
he capacity of health systems to support operational re-
Withtries
py Compared With
eloping Countries
Primary Prevention
Absolute Risk
Gross National Income  325 >15 >5
90 923 1,214 3,180
58 905 1,207 6,030
81 930 1,219 11,010
72 930 1,221 6,270
46 790 1,039 1,320
71 846 1,145 1,410
orld Health Organization recommends interventions3 times the gross
converting enzyme inhibitor, beta-blocker, and statin. Drugs for primary
ker, and statin. Data from Table 4 of Gaziano et al. (42), with permission.paredCoun
hera
Dev
>
8
8
8
8
7
7
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December 2, 2008:1817–25 Global Inequalities in Access to Cardiovascular Health CareVD prevention and control in these settings (51). The
ecently established Global Partnership to Stem the Growth
f Chronic Diseases, involving Ovations (a United Health
are subsidiary), the WHO, the National Institutes of
ealth, and the Oxford Health Alliance, incorporates the
romotion of such research within its objectives (52).
ural China: An Example
he policy challenges faced by the some of the world’s
argest populations are exemplified by the current situation
n rural China, where stroke, chronic obstructive airway
iseases, cancer, and heart disease are the 4 most important
ontributors to total disease burden. In 2005, 74 million
eaths (78% of total deaths) in China were caused by such
iseases and one-third of these were caused by CVD (53).
ven with China’s booming economy, these costs are
nsustainable. One of the downsides of the market reform
hat has led to China’s economic growth has been the
ecline in access to health care for the poor. The factors that
ave undermined access to services are the growing health
are costs, low levels of insurance coverage, and low levels of
ublic funding. This has meant that patients when faced
ith serious illness are often confronted with the choice of
ither forgoing treatment or financial catastrophe (54).
Most people in China have limited access to and little
apacity to pay for preventive cardiovascular treatments.
his is particularly true in rural areas, where health services
re less developed, income is low, and the population is
arge. Allied with this is a health care system very much
riented toward hospital-based care and treatment. Health
are providers in China are generally paid according to the
ervices provided, with commissions from the sale of med-
cines being a significant component. A byproduct of this is
hat it discourages prevention and encourages overtreatment
hrough, for example, the overuse of high-technology diag-
ostic tests, prescription of expensive drugs (often admin-
strated parenterally), and the prolongation of hospital
dmissions. Such incentives toward high-cost and often
nappropriate treatment have contributed to the gradual
rosion of community trust in primary health care services,
articularly in rural populations (54).
In rural China, primary health care workers typically hold no
ormal medical qualifications and only one-third have a tech-
ical school certificate (55). Additionally, most health care
orkers are trained only in the recognition and treatment of
nfectious diseases together with the management of child-
irth, and generally have very little or no training in the
ecognition and management of noncommunicable conditions.
owever, the market changes that have taken place in China
ver the past few decades have reduced the state’s support for
hese health care workers, and as a result they have come to
epend more and more on income generated by prescribing.
ver the same period, there has been a transformation of
atient expectations fueled by an awareness of increasing
edical technology and a preference for hospital treatment rven for the most basic of illnesses (54). Addressing this
ismatch between patient expectations and primary care
orkforce capacity is a key challenge for the Chinese govern-
ent that will necessitate policy changes to increase the skills
f primary health care workers and to improve the services that
hey provide. Such steps are urgently required to re-establish
atient confidence in the quality of primary health care
ervices.
To rectify this problem will require a system that provides
ew and existing health care workers with the skills and tools
o manage CVD. This will require a training program focused
n the detection of individuals with symptomatic CVD, those
ith a history of CVD, and those at very high risk of
ardiovascular events. It will also require training in the use of
roven low-cost treatments for symptom management (e.g.,
itrates, beta-blockers) and event prevention (e.g., aspirin,
iuretics, statins). This should be augmented by training in a
ystem of referral to hospitals for specialist care for those in
eed. Training in the maintenance of long-term follow-up and
he management of treatment adherence also would be ideal.
uch practices should be reinforced by the provision of a simple
edical record system. The cost of screening and therapy could
onceivably be reimbursed through the Cooperative Medical
chemes, a system of social health insurance that is currently
eing rolled out across China but at present covers mainly
ospital care (56). This may be affordable so long as treatment
rimarily comprises of generic drugs, which can be purchased
heaply on the international market (e.g., $1 per year for a
iuretic) (15,57). Incentives should also be provided to health
are workers for screening, detection, treatment, and follow-
p, as have been used in some higher-income settings. This
hange in practice would need to be supported by an improved
rug supply system that ensured the availability of quality
eneric products at a price that was closer to the wholesale rate.
hange would also be supported by separating prescriber and
ispenser functions, because this is essential to ensuring
vidence-based, rather than revenue-based, practice.
The implementation of low-cost disease surveillance pro-
rams would enable the effects of such changes of primary
ealth care practice to be documented. China already has a
ell-functioning sentinel surveillance system. Other systems
esigned specifically for resource-poor settings have been
ested and shown to be effective in rural populations elsewhere
n Asia (23). The implementation of such systems in rural
hina would also facilitate the conduct of health care delivery
esearch, through which it should be possible to evaluate the
ffects of various primary care strategies and help inform
ecisions about scaling up such strategies.
he Way Forward
nderlying all solutions to the inequalities in access to
ardiovascular care is the need for much greater transpar-
ncy in the setting of national and international priorities for
esource allocation. It is not necessarily the case that
educing the disparities in access requires prominent advo-
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iseases. The size of the CVD epidemic facing LMIC
peaks for itself, as does the strength of the evidence about
ow-cost interventions that can be delivered through pri-
ary health care services. If governments and funding
gencies really believe that health investments need to be
eared toward best buys based on evidence of cost and effect,
hen there needs to be much greater investment in primary
ealth care programs to prevent and treat CVD. Upgrading
rimary health care services would also have positive con-
equences for the management of other important chronic
onditions, including HIV infection. Achieving this, how-
ver, is unlikely to be straightforward, and there will
nevitably be major institutional and resource constraints
hat require any such reforms to be accompanied by pro-
rams geared toward, among other things, the training of
ealth care providers, the development of appropriate
uidelines for treatment, establishing appropriate incentives
or providers, ensuring reliable supplies of low-cost drugs,
nd taking measures to minimize the out-of-pocket costs to
atients of such treatments through financial protection
uch as insurance or direct state financing (Fig. 3).
A critical first step in the resolution of disparities in access
o care in LMIC settings is to establish locally relevant
emplates for acceptable and affordable primary health care
riented toward evidence-based, cost-effective strategies.
uch strategies would promote awareness and improve
ccess to prevention, early diagnosis, and early treatment.
Figure 3 Solutions to Reduce Inequalities in Access to CVD Ca
CVD  cardiovascular disease; LMIC  low- and middle-income countries.his would result in cost savings to individuals and theommunity as a consequence of reduced morbidity and
ortality, lower levels of hospitalization, and increased
conomic productivity. The results would have implications
or both the health and the wealth of the developing world.
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APPENDIX
or a list of high-income economies,
lease see the online version of this article.
